The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2022 | Strategies to manipulate the immune system in myeloid malignancies
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, outlines approaches to modulate the immune system in myeloid malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Whilst targeting T-cell immune checkpoint inhibitors (ICIs) such as PD-1 and PD-L1 has not been very successful, targeting other ICIs including CTLA-4, TIM-3, CD47/SIRPα, and manipulating natural killer (NK) cells has led to more promising results. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
